| Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy D Zhang, RM Reyes, E Osta, S Kari, HB Gupta, AS Padron, ... Cancer Medicine 10 (6), 2137-2152, 2021 | 32 | 2021 |
| CD122-Selective IL2 complexes reduce immunosuppression, promote Treg fragility, and sensitize tumor response to PD-L1 blockade JM Drerup, Y Deng, SL Pandeswara, ÁS Padrón, RM Reyes, X Zhang, ... Cancer research 80 (22), 5063-5075, 2020 | 30 | 2020 |
| Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study N Ji, N Mukherjee, RM Reyes, J Gelfond, M Javors, JJ Meeks, ... Journal for immunotherapy of cancer 9 (3), 2021 | 24 | 2021 |
| CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation RM Reyes, Y Deng, D Zhang, N Ji, N Mukherjee, K Wheeler, HB Gupta, ... Journal for Immunotherapy of cancer 9 (4), 2021 | 14 | 2021 |
| γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer N Ji, N Mukherjee, ZJ Shu, RM Reyes, JJ Meeks, DJ McConkey, ... Cancer Immunology Research 9 (12), 1491-1503, 2021 | 11 | 2021 |
| Immune checkpoint expression and relationships to anti‐PD‐L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice MG Garcia, Y Deng, C Murray, RM Reyes, A Padron, H Bai, A Kancharla, ... Aging and cancer 3 (1), 68-83, 2022 | 8 | 2022 |
| A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer RM Reyes, E Rios, S Barney, CM Hugen, JE Michalek, Y Lotan, ... Bladder Cancer 7 (3), 285-295, 2021 | 5 | 2021 |
| Urinary diversion disparity following radical cystectomy for bladder cancer in the Hispanic population EM Rios, MA Parma, RA Fernandez, TN Clinton, RM Reyes, D Kaushik, ... Urology 137, 66-71, 2020 | 4 | 2020 |
| CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation RM Reyes, C Zhang, Y Deng, N Ji, N Mukherjee, AS Padron, CA Clark, ... Oncoimmunology 10 (1), 2006529, 2021 | 2 | 2021 |
| Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1 … H Bai, AS Padron, Y Deng, YJ Liao, CJ Murray, C Ontiveros, SJ Kari, ... Journal for Immunotherapy of Cancer 11 (2), 2023 | 1 | 2023 |
| PHARMACOLOGIC TUMOR PD-L1 DEPLETION WITH CHLORAMBUCIL TREATS OVARIAN CANCER AND MELANOMAS IN A TUMOR PD-L1-DEPENDENT MANNER AND RENDERS alpha PD-L1-RESISTANT TUMORS alpha PD-L1 … H Bai, A Padron, Y Deng, A Kornepati, S Polusani, S Kari, C Murray, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 9, A261-A261, 2021 | 1 | 2021 |
| 234 Distinct efficacy and immunological responses to αPD-1, αPD-L1 and αPD-L2 immunotherapy in aged versus young hosts Y Deng, H Gupta, M Garcia, A Kancharla, R Reyes, A Padron, T Curiel Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 1 | 2021 |
| Tumor cell-intrinsic PD-L1 signals promote DNA damage responses that mediate resistance to Chk1 and PARP inhibitors in vivo AV Kornepati, D Zhang, AS Padron, JT Boyd, Y Deng, EG Osta, ... The Journal of Immunology 204 (1_Supplement), 241.33-241.33, 2020 | 1 | 2020 |
| CD122-selective IL-2 complexes treat ovarian carcinomas, possibly by dysregulating Treg differentiation and reducing suppression, and promoting T cell stem cells Y Deng, J Drerup, X Zhang, R Reyes, J Mendez, M Garcia, A Padron, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | 1 | 2019 |
| CD122-selective IL-2 complexes treat ovarian carcinomas and melanoma, alter Treg differentiation and induce more CD8+ CXCR5+ TCF-1+ stem T cells when combined with αPD-L1 Y Deng, HB Gupta, JM Drerup, RM Reyes, J Mendez, X Zhang, ... The Journal of Immunology 202 (1_Supplement), 136.15-136.15, 2019 | 1 | 2019 |
| Cell-intrinsic PD-L1 and PD-1 signal effects in bladder cancer D Zhang, X Sun, HB Gupta, RM Reyes, RS Svatek, TJ Curiel The Journal of Immunology 200 (1_Supplement), 166.27-166.27, 2018 | 1 | 2018 |
| 242 Pharmacologic tumor PD-L1 depletion with chlorambucil treats ovarian cancer and melanomas in a tumor PD-L1-dependent manner and renders αPD-L1-resistant tumors αPD-L1-sensitive H Bai, Á Padrón, Y Deng, A Kornepati, S Polusani, K Suresh, C Murray, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A261-A261, 2021 | | 2021 |
| Intracellular PD-L1 regulates DNA damage checkpoints and suppresses Chk1 and PARP inhibitor synthetic lethality AV Kornepati, Y Deng, E Dray, C Murray, SC Kari, E Osta, Z Liu, J Boyd, ... The Journal of Immunology 206 (1_Supplement), 67.15-67.15, 2021 | | 2021 |
| CD122-SELECTIVE IL-2 COMPLEXES TREAT OVARIAN CARCINOMAS, INDUCE TREG FRAGILITY AND PROMOTE T CELL STEM CELLS Y Deng, JM Drerup, X Zhang, RM Reyes, J Mendez, ME Raeber, ... The Journal of Immunology 206 (1_Supplement), 57.17-57.17, 2021 | | 2021 |
| Microenvironment-Specific Immunity alters Anti-Programmed Death Ligand 1 and Interleukin-2 Receptor-Targeted Immunotherapy Responses in Cancer RM Reyes The University of Texas Health Science Center at San Antonio, 2021 | | 2021 |
Tyler CurielDartmouth Health and Geisel School of Medicine at DartmouthVerified email at dartmouth.edu
